U.S. Food & Drug Administration Approves Genentech's Tecentriq in Combination With a Fluoropyrimidine, Oxaliplatin for Adjuvant Treatment of a Certain Type of Stage III Colon Cancer
October 10, 2026
October 10, 2026
SOUTH SAN FRANCISCO, California, Oct. 10 (TNSrep) -- Genentech, a member of the Roche Group, issued the following news release:
* * *
FDA Approves Genentech's Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for The Adjuvant Treatment of a Certain Type of Stage III Colon Cancer
* FDA approval is based on results from the landmark Phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemot . . .
* * *
FDA Approves Genentech's Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for The Adjuvant Treatment of a Certain Type of Stage III Colon Cancer
* FDA approval is based on results from the landmark Phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemot . . .